Carsyon III E Learning-march

25 Questions | Total Attempts: 47

SettingsSettingsSettings
Carsyon III E Learning-march - Quiz

Welcome to March E-Learning TestYou have 20 minutes to complete this test. Please enter your name and Emp. Code and press "Start" to begin the test. You can only attend the test once and hence make sure you are uninterrupted internet connectivity. Please click on the link to read the study materialhttps://www. Proprofs. Com/training/course/? Title=carsyon-3-study-materia l_1All the bestMicro Leadership Academy


Questions and Answers
  • 1. 
    The number of people with hypertension is predicted to be ------- worldwide by the year 2025.
    • A. 

      1.56 billion

    • B. 

      1.56 million

    • C. 

      15.6 billion

    • D. 

      156 billion

  • 2. 
    The force exerted by the flowing blood against the walls of blood vessels is called -----.
    • A. 

      Cardiac output

    • B. 

      Stroke volume

    • C. 

      Blood pressure

    • D. 

      Hypertension

  • 3. 
    Hypertension is having a blood pressure
    • A. 

      Higher than 120/80 mm.of Hg.

    • B. 

      Higher than 140/90 mm.of Hg.

    • C. 

      Higher than 140/80 mm.of Hg.

    • D. 

      Lower than 120/80 mm.of Hg.

  • 4. 
    Hypertension is responsible for ------% of all stroke deaths in India.
    • A. 

      24

    • B. 

      59

    • C. 

      57

    • D. 

      75

  • 5. 
    Hypertension is responsible for -----% of all coronary heart disease deaths in India.
    • A. 

      24

    • B. 

      42

    • C. 

      57

    • D. 

      27

  • 6. 
    Combining two or more anti hypertensive agents from different classes in a single tablet helps in 
    • A. 

      Reducing the pill burden

    • B. 

      Adherence to therapy

    • C. 

      Compliance to therapy

    • D. 

      All of the above

  • 7. 
    Nulong trio is a combination of 
    • A. 

      An ACE inhibitor, an ARB and a CCB.

    • B. 

      An ARB, a CCB & a diuretic.

    • C. 

      An ARB, a CCB and a statin.

    • D. 

      An ARB, a Diuretic and a fibrate.

  • 8. 
    Nulong trio is a combination of 
    • A. 

      Olmesartan, Amlodipine & Hydrochlorothiazide.

    • B. 

      Olmesartan, Cilnidipine & Hydrochlorothiazide.

    • C. 

      Olmesartan, Cilnidipine & Chlorthalidone.

    • D. 

      Olmesartan, Amlodipine & Chlorthalidone.

  • 9. 
    Nulong trio offers
    • A. 

      Once daily dosing convenience

    • B. 

      Cost effectiveness

    • C. 

      Both of the above

    • D. 

      None of the above

  • 10. 
    Onset of  antihypertensive action of Olmesartan is ------------ as compared to other ARBs like Losartan,Valsartan & Irbesartan.
    • A. 

      Faster

    • B. 

      Same

    • C. 

      Slower

    • D. 

      None of the above

  • 11. 
    Cilnidipine has calcium channel blocking activity of 
    • A. 

      Only N type

    • B. 

      Only L type

    • C. 

      Both N and L type

    • D. 

      Neither N or L type

  • 12. 
    Cilnidipine 
    • A. 

      Decreases urinary albumin excretion in hypertensive patients

    • B. 

      Increases urinary albumin excretion in hypertensive patients

    • C. 

      Has no effect on urinary albumin excretion in hypertensive patients

    • D. 

      None of the above

  • 13. 
     As per the CARTER  (trial), Cilnidipine is -------  Amlodipine in preventing the progression of proteinuria in hypertensive patients .
    • A. 

      As effective as

    • B. 

      Less effective than

    • C. 

      Superior to

    • D. 

      None of the above

  • 14. 
    Cilnidipine
    • A. 

      Causes severe ankle edema

    • B. 

      Does not cause reflex tachycardia

    • C. 

      Causes reflex tachycardia

    • D. 

      None of the above

  • 15. 
    Nulong trio is ideal for 
    • A. 

      Patients with uncontrolled and resistant hypertension.

    • B. 

      Patients with co morbid renal conditions

    • C. 

      Patients with co morbid CV disease

    • D. 

      All of the above

  • 16. 
    Chlorthalidone has --------half life as compared to HCTZ.
    • A. 

      Same

    • B. 

      Shorter

    • C. 

      Longer

    • D. 

      None of the above

  • 17. 
    CHD, Stroke, LVH & MI are diseases attributable to 
    • A. 

      Hypotension

    • B. 

      Hypertension

    • C. 

      Vitamin deficiency

    • D. 

      Antioxidants

  • 18. 
    -------------- is the single largest contributor to global mortality.
    • A. 

      Retinopathy

    • B. 

      Nephropathy

    • C. 

      Neuropathy

    • D. 

      Arterial hypertension

  • 19. 
    In patients less than 55 years of age, newly diagnosed with hypertension, the drug of choice is
    • A. 

      CCB

    • B. 

      Diuretic

    • C. 

      ACE Inhibitor or ARB

    • D. 

      None of the above

  • 20. 
    In patients 55 years or older, newly diagnosed with hypertension, the choice of drug is 
    • A. 

      ACE inhibitor

    • B. 

      ARB

    • C. 

      CCB or Thiazide type Diuretic

    • D. 

      None of the above

  • 21. 
    Angiotensinogen is converted to Angiotensin I by the action of 
    • A. 

      ACE

    • B. 

      Renin

    • C. 

      Angiotensin II

    • D. 

      All of the above

  • 22. 
    ACE converts
    • A. 

      Angiotensinogen to Angiotensin I

    • B. 

      Angiotensin I to Angiotensin II

    • C. 

      Angiotensin II to Angiotensin I

    • D. 

      None of the above

  • 23. 
    When Angiotensin II binds to AT2 receptor ,there is 
    • A. 

      Vasodilation

    • B. 

      Vasoconstriction

    • C. 

      Both of the above

    • D. 

      None of the above

  • 24. 
    ------------- effect of Cilnidipine is greater than pure L-type CCBs.
    • A. 

      Renoprotective

    • B. 

      Retinopathy

    • C. 

      Neuropathy

    • D. 

      None of the above

  • 25. 
    When Angiotensin II binds to AT1 receptor  ,there is 
    • A. 

      Vasoconstriction

    • B. 

      Vasodilation

    • C. 

      Both of the above

    • D. 

      None of the above

Back to Top Back to top